Letrozol Combix

Letrozole, the active ingredient in Letrozol Combix, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen production that can fuel tumor growth.

GNH USA supplies Letrozol Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable distribution across global markets.

Letrozol Combix acts on estrogen‑dependent breast cancer pathways and is indicated for the following conditions: - Hormone receptor‑positive breast cancer in postmenopausal women: lowers estrogen levels to inhibit tumor growth. - Adjuvant therapy for early‑stage disease: reduces risk of recurrence after surgery. - Metastatic breast cancer in postmenopausal patients: helps control disease progression when other hormonal therapies are unsuitable.

Letrozol Combix may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint pain: aching or stiffness in muscles and joints. - Fatigue: persistent tiredness not relieved by rest. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, elevated liver enzymes. - Bone fracture: increased risk due to lowered estrogen. - Deep vein thrombosis: swelling, pain, redness in a limb. - Severe allergic reaction: rash, swelling, difficulty breathing.

Before initiating therapy, clinicians should consider several safety measures. - Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess bone health: consider calcium and vitamin D supplementation and periodic bone density scans. - Evaluate cardiovascular risk: watch for signs of thrombosis or embolism. - Avoid use in pregnancy: contraindicated for women of childbearing potential. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Letrozol Combix can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes letrozole’s effect, reducing efficacy. - Strong CYP2A6 inhibitors (e.g., methoxsalen): may increase letrozole plasma levels.

Moderate Interactions (Monitor Closely): - Tamoxifen: opposing mechanisms may diminish therapeutic benefit. - Certain SSRIs (e.g., fluoxetine): may modestly affect metabolism. - Glucocorticoids: may increase risk of bone loss when combined.